Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01815840 · ClinicalTrials.gov registry record · Phase 2
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
NCT01815840 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 229 participants.
The verdict
NCT01815840, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
Study Summary
This randomized, double-blind, regimen-controlled, phase II, multicenter study will assess the efficacy and safety of two different vismodegib regimens in participants with multiple basal cell carcinoma. Participants will receive vismodegib 150 mg orally once daily either in an intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo (Arm A) or as 24 weeks induction followed by an intermittent schedule of 8 weeks placebo followed by 8 weeks vismodegib (Arm B). Anticipated time on study treatment is 72 weeks.
Interventions
- DRUG Placebo
- DRUG Vismodegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2013-04-30 |
| Est. Completion | 2016-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01815840
The ClinicalTrials.gov registry entry for NCT01815840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01815840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01815840 about?
NCT01815840 is a clinical study titled "A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas". This randomized, double-blind, regimen-controlled, phase II, multicenter study will assess the efficacy and safety of two different vismodegib regimens in participants with multiple basal cell carcinoma. Participants will receive vismodegib 150 mg orally once daily either in an intermittent schedule...
What is the current status of trial NCT01815840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2013-04-30. Estimated completion is 2016-08-31.
What interventions are being tested in trial NCT01815840?
The interventions under investigation include: Placebo (DRUG), Vismodegib (DRUG).
Who is sponsoring clinical trial NCT01815840?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.